HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chattem

This article was originally published in The Rose Sheet

Executive Summary

Phisoderm body wash and acne masque will debut in 2002 to fuel firm's acne cleanser business and boost flagging skin care sales, Chattem announces. Chattanooga, Tenn.-based marketer reports double-digit sales declines in skin care division in the fiscal third quarter ended Aug. 31. Declines partially were offset by resurgence in firm's Gold Bond business, which registered 8%, 18% and 10% increases in adult powder, foot powder and cream products, respectively, according to the company. Gold Bond Foot Spray will be added to line in 2002. Third quarter net sales decrease of 32.2% to $49.6 mil. also reflects sale of Ban antiperspirants and deodorants, which generated $21.5 mil. in the year-ago period, Chattem notes. Net income, including extraordinary loss on early extinguishment of debt, down 60% to $2.1 mil. in the third quarter

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009638

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel